Department of Orthopaedic Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Resident in Orthopaedic Surgery, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, UK.
Bone Joint J. 2019 Aug;101-B(8):891-896. doi: 10.1302/0301-620X.101B8.BJJ-2019-0037.R1.
There is good scientific rationale to support the use of growth factors to promote musculoskeletal tissue regeneration. However, the clinical effectiveness of platelet-rich plasma (PRP) and other blood-derived products has yet to be proven. Characterization and reporting of PRP preparation protocols utilized in clinical trials for the treatment of musculoskeletal disease is highly inconsistent, and the majority of studies do not provide sufficient information to allow the protocols to be reproduced. Furthermore, the reporting of blood-derived products in orthopaedics is limited by the multiple PRP classification systems available, which makes comparison of results between studies challenging. Several attempts have been made to characterize and classify PRP; however, no consensus has been reached, and there is lack of a comprehensive and validated classification. In this annotation, we outline existing systems used to classify preparations of PRP, highlighting their advantages and limitations. There remains a need for standardized universal nomenclature to describe biological therapies, as well as a comprehensive and reproducible classification system for autologous blood-derived products. Cite this article: 2019;101-B:891-896.
有充分的科学依据支持使用生长因子来促进肌肉骨骼组织再生。然而，富血小板血浆（PRP）和其他血液衍生产品的临床疗效尚未得到证实。在治疗肌肉骨骼疾病的临床试验中，PRP 制备方案的特征描述和报告非常不一致，大多数研究没有提供足够的信息来复制这些方案。此外，由于现有的多种 PRP 分类系统，骨科中血液衍生产品的报告受到限制，这使得研究之间的结果比较具有挑战性。已经有几次尝试对 PRP 进行特征描述和分类；然而，尚未达成共识，也缺乏全面和经过验证的分类。在本注释中，我们概述了用于分类 PRP 制剂的现有系统，强调了它们的优点和局限性。仍然需要标准化的通用命名法来描述生物疗法，以及用于自体血液衍生产品的全面和可重复的分类系统。
2019；101-B:891-896.
